HCW Biologics Inc. — FY2022 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2022. The filing reports annual results and does not provide a clear standalone fourth-quarter financial breakdown. HCW Biologics (Nasdaq: HCWB) is a clinical-stage biopharmaceutical company developing immunotherapies for cancer and other age-related inflammatory diseases. Its lead clinical candidate is HCW9218; HCW9302 remained preclinical.
Financial results and liquidity
| Metric | FY2022 | FY2021 |
|---|---|---|
| Revenue | $6.72 million | $0 |
| Cost of revenue | $4.14 million | $0 |
| Net revenue after cost of revenue | $2.59 million | $0 |
| Research and development expense | $9.34 million | $8.17 million |
| General and administrative expense | $8.33 million | $5.19 million |
| Operating loss | $15.08 million | $13.37 million |
| Net loss | $14.90 million | $12.86 million |
| Net loss per share, basic and diluted | $0.42 | $0.69 |
| Cash used in operating activities | $10.39 million | $10.98 million |
- FY2022 revenue came from Wugen-related clinical and research material supply, not product sales. The company has no approved products or commercial product revenue. Net revenue after cost of revenue was approximately 38.5% of revenue.
- R&D expense rose 14%, reflecting higher clinical-trial and IND-enabling costs. G&A rose 60%, including higher legal, insurance, compensation and public-company costs. Operating loss increased about 13% and net loss about 16%.
- At year-end, cash and cash equivalents were $22.33 million and short-term investments were $9.74 million; current assets were $34.07 million and current liabilities $2.96 million. Management said these liquid resources were expected to fund operations for at least 12 months, based on assumptions.
- Debt was $6.5 million gross, secured by the new headquarters building; the balance sheet reported $6.41 million of debt, net. The loan bears fixed interest of 5.75%, with interest-only payments for the first year and a 2027 maturity that includes a balloon payment. The company reported compliance with loan covenants.
- Total assets were $46.81 million and stockholders’ equity was $37.43 million. Cash provided by investing activities was $14.71 million, mainly reflecting $24.98 million of investment maturities offset by about $10.28 million of property and equipment purchases. Financing provided $6.27 million, primarily from the building loan.
Business developments, outlook and risks
- HCW9218 was being studied in two early-stage cancer trials: a company-sponsored Phase 1b/2 trial in advanced pancreatic cancer and an investigator-sponsored Phase 1 solid-tumor trial. No dose-limiting toxicities had been reported in either trial as of the filing. Preliminary human findings included immune-cell activity and reduced serum TGF-β; these are early, non-definitive results.
- Management expected to complete the pancreatic trial’s Phase 1b portion in 2023 and pursue Phase 2 development, subject to trial results, dose selection and FDA authorization. HCW9302 IND-enabling work was expected to finish in the first half of 2023, with an IND submission planned for the second half; neither timing nor FDA clearance was assured.
- The company purchased a 36,000-square-foot Miramar building for approximately $10.1 million, partly financed with the loan. It planned to refit the site for research and potential clinical manufacturing, with operations expected in the second half of 2024; the schedule could be delayed to preserve cash. It continued to rely on third-party manufacturers and had no long-term supply arrangements.
- The Wugen license provides potential development and commercial milestones exceeding $200 million and single-digit royalties, but these payments are contingent and not assured. HCW Biologics also holds a 5.8% interest in private Wugen shares, which are not publicly traded.
- A material contingency is litigation brought by Altor BioScience and NantCell in December 2022, alleging trade-secret misappropriation and related claims, including seeking rights to certain patents and applications. The company disputed the claims; the court proceedings and related CEO arbitration were ongoing. The company said potential loss could not be reasonably estimated and recorded no accrual. It expected material legal costs in 2023.
- Other cited risks include continuing operating losses and possible need for additional capital; clinical, regulatory and patient-enrollment uncertainty; manufacturing and supply-chain dependence; inflation and geopolitical disruption; and the possibility that preliminary trial data change. Management said it had no exposure to the failed Silicon Valley Bank.
- Independent auditors issued an unqualified opinion on the financial statements. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not attest to internal-control effectiveness because the company used the emerging-growth-company exemption.
Most important facts for investors to verify
- Current cash, investment balances, spending pace and whether the stated 12-month runway remains achievable.
- Updated HCW9218 trial enrollment, safety, dose selection and efficacy data, and whether the FDA permits planned Phase 2 studies.
- HCW9302 toxicology, IND submission timing and FDA response.
- Developments in the Altor/NantCell litigation, including potential effects on intellectual property, legal spending and the company’s financial position.
- Future Wugen material-supply revenue and whether any contingent license milestones or royalties are achieved.
- Costs and timing for the headquarters refit, manufacturing-equipment commitment and transition to any in-house manufacturing capability.